Cart summary

You have no items in your shopping cart.

Atorvastatin hemicalcium

SKU: orb1226500

Description

A competitive inhibitor of HMG-CoA reductase (HMGCR) that acts as a lipid-lowering agent for prevention of events associated with cardiovascular disease.Dyslipidemia Approved(In Vitro):Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation.(In Vivo):Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE / mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment.

Images & Validation

Key Properties

CAS Number134523-03-8
MW557.6324
Purity>98% (HPLC)
FormulaC33H34FN2O5-
SMILESCC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2]
TargetHMGCR
Solubility10 mM in DMSO

Bioactivity

In Vivo
Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE / mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/-mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment. Animal model: Forty 8-week-old ApoE / mice induced with angiotensin II (Ang II). Dosage: 20 mg/kg, 30 mg/kg. Administration: Oral gavage; once a day; for 28 days. Result: Significantly reduced ER stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE / mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β were all remarkably inhibited.
In Vitro
Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Atorvastatin hemicalcium

Similar Products

Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Atorvastatin hemicalcium (orb1226500)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

10 mg
$ 90.00
25 mg
$ 100.00
50 mg
$ 110.00
100 mg
$ 160.00
200 mg
$ 240.00
500 mg
$ 430.00